
What We’re Reading: CMS Finalizes MA Protections; Digital Treatment for MDD; Paxlovid Efficacy in the Fully Vaccinated
CMS finalizes policies to enhance consumer protections, promote competition, and expand access to care for Medicare Advantage (MA) and Medicare Part D; digital therapeutic Rejoyn receives FDA clearance for adults with major depressive disorder (MDD); study reveals minimal symptom reduction from nirmatrelvir–ritonavir (Paxlovid) in high-risk, fully vaccinated patients.
CMS Strengthens Protections, Access for MA, Part D Enrollees
CMS announced the finalization of policies that aim to increase enrollee protections and enhance access to care in Medicare Advantage (MA) and Medicare Part D prescription drug plans,
FDA Approves First Prescription Digital Treatment for Adults With MDD
The FDA has authorized the use of Rejoyn, the first prescription digital treatment for adults with major depressive disorder (MDD),
Limited Efficacy of Paxlovid in Fully Vaccinated Individuals
A recent study showed nirmatrelvir–ritonavir (Paxlovid) showed little efficacy in reducing symptoms among fully vaccinated individuals with COVID-19 risk factors,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.